We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » SAVIENT URGES BE STUDIES FOR OXANDRALONE PRODUCTS
SAVIENT URGES BE STUDIES FOR OXANDRALONE PRODUCTS
February 20, 2004
Savient Pharmaceuticals has asked the FDA to require bioequivalency (BE) evidence for all oral products containing oxandralone to show that they interact with anticoagulants containing warfarin in the same way that Savient’s brand version of oxandralone does.